What to Expect at AACR 2025: Nuvalent to present Data on Neladalkib and Zidesamtinib

Upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, to be held April 25-30, 2025, in Chicago, Illinois, include novel data characterizing the preclinical profiles of Nuvalent’s novel ALK-selective inhibitor, neladalkib (NVL-655), and novel ROS1-selective inhibitor, zidesamtinib (NVL-520).

Authors

Peter Hofland (ORCID: https://orcid.org/0000-0002-8025-0434)

Publication Details

Journal: Onco Zine - The International Oncology Network
Published: 2025-03-29
DOI: https://doi.org/10.14229/onco.2025.03.29.001
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

What to Expect at AACR 2025: Nuvalent to present Data on Neladalkib and Zidesamtinib

Peter Hofland

Mar 29, 2025

Onco Zine - The International Oncology Network

Lung Cancer Treatments and Mutations

article

What to Expect at AACR 2025: Nuvalent to present Data on Neladalkib and Zidesamtinib

Peter Hofland

March 29, 2025article en

Abstract

Onco Zine - The International Oncology Network

Openalex Percentile: Top 90%

Lung Cancer Treatments and Mutations

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

What to Expect at AACR 2025: Nuvalent to present Data on Neladalkib and Zidesamtinib — Peter Hofland · Onco Zine - The International Oncology Network (2025) | TGRS Research Map | TGRS